Secondary hemophagocytic lymphohistiocytosis due to nivolumab/ipilimumab in a renal cell cancer patient-A case report

Adeel Masood; Ahsan Wahab; Tanya Clifford; Eric J Weaver; Hamid Ehsan; Walid El Ayass

doi:10.1002/ccr3.5184

Secondary hemophagocytic lymphohistiocytosis due to nivolumab/ipilimumab in a renal cell cancer patient-A case report

Clin Case Rep. 2021 Dec 5;9(12):e05184. doi: 10.1002/ccr3.5184. eCollection 2021 Dec.

Authors

Adeel Masood^{1

2}, Ahsan Wahab³, Tanya Clifford², Eric J Weaver², Hamid Ehsan⁴, Walid El Ayass²

Affiliations

¹ Masters of Public Health in Epidemiology at the University of Alabama at Birmingham Alabama USA.
² Tidal Health Peninsula Regional Salisbury Maryland USA.
³ Baptist Medical Center South University of Alabama at Birmingham Montgomery Alabama USA.
⁴ Levine Cancer Institute/Atrium Health Charlotte North Carolina USA.

Abstract

Secondary immune-related hemophagocytic lymphohistiocytosis is a rare but life-threatening complication of immune checkpoint inhibitors. HLH-2004 and HLH-1994 guidelines originally developed for primary HLH are the only available guidelines. It has proven to have a good prognosis if diagnosed promptly with discontinuation of immunotherapy and treated with corticosteroid monotherapy.

Keywords: HLH; hematology/oncology; immune checkpoint inhibitors; ipilimumab; nivolumab; pembrolizumab; secondary hemophagocytic lymphohistiocytosis.

Publication types

Case Reports